Study Examines Association Between Undifferentiated Pruritus and Hematologic Cancers
The careful consideration of cancer risk is especially important during the first year after the presentation of pruritus.
Diagnosis & Disease Information
Optimizing Outcomes in Low-Risk Myelodysplastic Syndromes
Diagnosis, goals of care, and treatment options for MDS are discussed in a presentation at 2022 ONA Summit.
Venetoclax/Azacitidine Combination Efficacious for the Treatment of Older Patients With Higher-Risk Myelodysplastic Syndrome
Combination therapy positively influenced overall survival rates, dyspnea, and fatigue through 48 weeks in this patient population.
Effects of 5-Azacitidine Dose Changes With Myelodysplastic Syndrome
For patients with myelodysplastic syndrome, 5-azacitidine treatment delays showed some links to outcomes, while dose reductions had less impact.
Inqovi, an Oral Therapy for Myelodysplastic Syndromes, Gets FDA Approval
The administration of cedazuridine with decitabine prevents the degradation of decitabine by CDA in the gastrointestinal tract and liver increasing its systemic exposure.
SF3B1 Mutation in Clonal Cytopenia of Undetermined Significance Strongly Linked to Myelodysplastic Syndrome Development
Given the prevalence, the IWG-PM evaluated available evidence to determine whether SF3B1-mutated MDS should be recognized as a distinct disease subtype.
Outpatient Induction Chemotherapy for Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
With adequate support from a multidisciplinary care team, outpatient induction chemotherapy was safe for these patients.
Luspatercept Mitigates Anemia in Lower-Risk Myelodysplastic Syndromes
Transfusion burden reduced in patients with lower-risk myelodysplastic syndromes with ring sideroblasts.
Outcomes Improved for Patients With AML and MDS Receiving Treosulfan/Fludarabine vs Busulfan/Fludarabine Conditioning Prior to HSCT
Researchers sought to determine if nonmyeloablative HSCT conditioning was noninferior to myeloablative approaches in more vulnerable patients with AML.
Risk of Therapy-Related MDS, AML Increased by Use of Leukemogenic Chemotherapy Agents
Researchers sought to determine the association between chemotherapy, particularly platinum-based agents, and increased risk of tMDS/AML.
- Loading...
Loading...
Next post in Leukemia
Loading... 
Loading...